Bank hails Zealand Pharma's data as "home run"
![Photo: Zealand Pharma / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14415586.ece/ALTERNATES/schema-16_9/doc7mtanwwcee9ag00hi2p.jpg)
Zealand Pharma’s successful phase III trial of glepaglutide, a potential short bowel syndrome treatment, has been met with enthusiasm from analysts, including those at Danske Bank, which describes the study as nothing short of a ”home run” in a note.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Zealand Pharma will have crucial data ready in few weeks
For subscribers